logo
Sign in

IO THERAPEUTICS, INC.

SPRING, TX · Founded 2010 · Biotech · Private

IRX4204, a synthetic oral RXR nuclear receptor agonist for multiple sclerosis treatment

Claim this profile

Follows are private to you and power your alerts

Updated · io-therapeutics.com

Sector
Biotech
Headquarters
SPRING, TX
Founded
2010
Latest Form D
$4.2M, Mar 2023
Total capital
$8.3M
Federal grants
$3.7M
3 awards · 2016–2017
Rank in peer group#259 of 514
Private capital raised
$4.6M
2 Form D · last Mar 2023
44 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
29
11 pending · first 2020
Rank in peer group#2 of 514

Capital timeline

20142016201820202022FEDERAL ↑EQUITY ↓Cumulative $8.3M$854K$1.9M$1M1st Form D$444K2nd Form D$4.2M
20142016201820202022FEDERAL ↑EQUITY ↓Cumulative $8.3M$1.9M$1M1st Form D$444K2nd Form D$4.2M

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$4.2M
  • Federal grantHealth and Human S · Phase II · Development of the RXR agonist IRX4204 to treat Multiple Sclerosis and other Immune related Diseases$1M
  • Federal grantHealth and Human S · Phase II · Development of the RXR agonist IRX to treat Multiple Sclerosis and other Immune related Diseases$1.9M
  • Federal grantHealth and Human S · Phase II · Development of the RXR agonist IRX4204 to treat Multiple Sclerosis and other Immune related Diseases$854K
  • Private capital raisedForm D · SEC · 1st filing$444K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median
  • Granted patents#2 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Vidyasagar VuligondaResearcherExecutive OfficerLinked by 3 patents
  • Martin SandersResearcherExecutive OfficerLinked by 2 patents
  • Roshantha A. ChandraratnaResearcherExecutive Officer, DirectorLinked by 2 patents
  • Sahani ChandraratnaDirectorNamed in SEC Form D filings
  • Scott A. ThacherDirectorNamed in SEC Form D filings
  • Sharon LewExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 29 granted of 40
  • PendingTreatment Of Nervous System Disorders Using Combinations Of Rxr Agonists And Thyroid HormonesUSPTOApplication 19187713
  • GrantedRxr Agonist Salt Form, Polymorphs Thereof, And Uses ThereofUSPTOUS 12,325,685
  • PendingMETHODS OF USING RARy AGONISTS FOR CANCER TREATMENTUSPTOApplication 18905646
Show all 40 patent records

Related companies, and why

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .